Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | GSR | P00390 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6401479 | 1.00 | TRPA1 (0.45) | TRPA1LMNAHTR2ATAAR1GSR | |
| SCHEMBL1408602 | 1.00 | TRPA1 (0.45) | TRPA1LMNAHTR2ATAAR1GSR | |
| SCHEMBL3203278 | 0.80 | TRPA1 (0.48) | TRPA1LMNAHTR2ATAAR1KDM4E | |
| SCHEMBL13473250 | 0.79 | LMNA (0.58) | TRPA1LMNAHTR2ATAAR1 | |
| SCHEMBL879168 | 0.79 | LMNA (0.58) | TRPA1LMNAHTR2ATAAR1 | |
| SCHEMBL577036 | 0.79 | LMNA (0.58) | TRPA1LMNAHTR2ATAAR1 | |
| SCHEMBL8443421 | 0.78 | HRH1 (0.46) | HTR2ATAAR1DPP4TSHR | |
| SCHEMBL10700271 | 0.78 | HTR2A (0.43) | LMNAHTR2ATAAR1DPP4TSHR | |
| SCHEMBL11225849 | 0.77 | ESR1 (0.44) | LMNATAAR1KDM4ECYP2D6TSHR | |
| SCHEMBL647478 | 0.76 | HTR2A (0.42) | HTR2ATAAR1DPP4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334888-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | GENZYME CORPORATION | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334888-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | UGCG, UGGT1, DPAGT1 | TRPA1 4818/4885LMNA 4349/4885HTR2A 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.